ImmunityBio (IBRX) Net Equity Issued and Repurchased (2014 - 2026)

ImmunityBio (IBRX) has reported Net Equity Issued and Repurchased for 9 consecutive years, with $53.7 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Net Equity Issued and Repurchased rose 215076.0% year-over-year to $53.7 million; the TTM figure through Dec 2025 stood at $227.4 million (up 6216.69% YoY), while the FY2025 annual figure was $400.6 million, up 11026.72% from the prior year.
• Net Equity Issued and Repurchased fell to $53.7 million in Q4 2025 per IBRX's latest filing, from $173.7 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $173.7 million in Q3 2025 and bottomed at -$91.2 million in Q4 2023.
• Historically, Net Equity Issued and Repurchased has averaged $30.3 million across 5 years, with a median of $27.6 million in 2021.
• Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased tumbled 250.93% — and 2025, when it jumped 215076.0%.
• ImmunityBio's Net Equity Issued and Repurchased stood at $27.6 million in 2021, then soared by 119.08% to $60.4 million in 2022, then sank by 250.93% to -$91.2 million in 2023, then jumped by 99.97% to -$25000.0 in 2024, then surged by 215076.0% to $53.7 million in 2025.
• Business Quant data shows IBRX's Net Equity Issued and Repurchased at $53.7 million in Q4 2025, $173.7 million in Q3 2025, and -$25000.0 in Q4 2024.